Jane Street Group LLC Sells 18,540 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

Jane Street Group LLC decreased its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 2.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 649,960 shares of the company’s stock after selling 18,540 shares during the period. Jane Street Group LLC owned about 0.72% of Caribou Biosciences worth $1,274,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Renaissance Technologies LLC purchased a new position in Caribou Biosciences in the second quarter worth about $2,432,000. Dimensional Fund Advisors LP lifted its stake in shares of Caribou Biosciences by 25.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after purchasing an additional 536,162 shares during the period. Exchange Traded Concepts LLC boosted its holdings in shares of Caribou Biosciences by 103.5% in the third quarter. Exchange Traded Concepts LLC now owns 82,494 shares of the company’s stock worth $162,000 after buying an additional 41,948 shares during the last quarter. Point72 DIFC Ltd grew its position in Caribou Biosciences by 389.4% during the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock valued at $49,000 after buying an additional 23,995 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in Caribou Biosciences during the second quarter valued at approximately $30,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Price Performance

CRBU opened at $1.67 on Friday. The company has a 50 day simple moving average of $2.06 and a two-hundred day simple moving average of $2.01. The firm has a market cap of $151.22 million, a P/E ratio of -1.01 and a beta of 2.27. Caribou Biosciences, Inc. has a 1-year low of $1.50 and a 1-year high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. The company had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. Equities analysts anticipate that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Citigroup dropped their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 26th. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Caribou Biosciences in a research report on Friday, November 15th. Four analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $10.20.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.